Market Cap
$54.2M
ANVS
Annovis Bio, Inc.
$1.18 ▲ +0.85%
Prev close $1.17Market cap$54.2M
ConsensusStrong Buy
12-mo target$10.50 (+789.8%)
▲ Bullish
Analyst conviction 9/10
High Impact Filing (7/10)8 New Institutional Positions5 Institutional Exits Biotech & Drug Discovery
Snapshot
The big-picture read on ANVS right now — valuation, ownership and activity at a glance.
Cap Size
Micro Cap
Analyst Consensus
Strong Buy (89%)
Inst. Holders
39 funds
Inst. Value
$17.0M
Inst. Activity
8 buys / 5 sells
Insider Activity
$1.6M buy / $0.00 sell
Insider Net $
$1.6M
Social Sentiment
57° Neutral
SEC Reports
6
Press Releases
2
Price chart 30d -14.5%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Sep 28, 2026 short_volume
Jul 10, 2026 SEC Short Volume: ANVS — 58.9% short (0.4M / 0.7M)
Short: 423,758 | Exempt: 2,589 | TRF Vol: 719,422 | Short Ratio: 58.9% | Off-exchange volume (dark p
Annovis Bio announced full enrollment of its pivotal Phase 3 trial (NCT06709014) of buntanetap for early Alzheimer's dis
8-K — Impact 6/10
Jun 30, 2026 Inst.
MARSHALL WACE, LLP — ADD
1,842,339 shares ($3.4M)
Jun 30, 2026 Inst.
May 20, 2026 SEC VANGUARD CAPITAL MANAGEMENT LLC — ADD
1,647,322 shares ($3.1M)
Annovis Bio is raising approximately $13.8M in net proceeds through a dilutive offering of 7.9M shares and warrants, pri
424B5 — Impact 6/10
May 20, 2026 Insider
Hoffman Michael B bought 54,933 shares
Director @ $1.90 ($104.4K)
May 20, 2026 Insider
Hoffman Michael B bought 18,849 shares
Director @ $1.80 ($33.9K)
May 20, 2026 Insider
Hoffman Michael B bought 2,562 shares
Director @ $1.75 ($4.5K)
Analyst ratings buy % -1.1%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
89% rate it Buy or better · 9 analysts
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Aug 28, 2026 | Roth Capital | MAINTAIN | Buy | 56% |
| Aug 18, 2026 | Canaccord Genuity | MAINTAIN | Buy | 47% |
| Jul 8, 2026 | Roth Capital | INITIATE | Buy | 56% |
| Apr 14, 2026 | Canaccord Genuity | MAINTAIN | Buy | 47% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 2 | 6 | 1 | 0 | 0 | 89% | |
| Aug 1, 2026 | 2 | 6 | 1 | 0 | 0 | 89% | |
| Jul 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% | |
| Jun 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% | |
| May 1, 2026 | 2 | 7 | 1 | 0 | 0 | 90% | |
| Apr 1, 2026 | 2 | 7 | 1 | 0 | 0 | 90% | |
| Mar 1, 2026 | 2 | 7 | 1 | 0 | 0 | 90% | |
| Feb 1, 2026 | 2 | 7 | 1 | 0 | 0 | 90% |
Price targets
Where 4 covering analysts think ANVS trades over the next 12 months.
$10.50 +789.8% upside Strong Buy
Current$1.18 Low$7.00 Median$9.00 High$17.00 4 analysts
$7.00$17.00
Analyst rating None as of Oct 2, 2026
Social media sentiment mood +31.8%
Retail-investor mood aggregated across social media. 0° = very bearish, 100° = very bullish.
57°
Neutral
BearishNeutralBullish
Recent posts
GANX Phase 2 in Q3. ANVS has going concern language. AVXL has $131M cash but CHMP rejection. Spread between them is wide. Anyone else tracking these?
▲ 1 · 💬 1· ⚡ 0.3
Parkinson's Watchlist: Risk breakdown: GANX = early data, high dilution risk. ANVS = late-stage assets, balance sheet stress. AVXL = financial cushion, regulatory uncertainty. Pick your poison.
▲ 1 · 💬 1· ⚡ 0.5
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
6 SEC filing reports analyzed · 0 bullish, 3 bearish, 2 mixed, 1 neutral · avg impact 6.0/10.Plus 2 press releases.
NEUTRAL8-K6/10
Annovis Bio announced full enrollment of its pivotal Phase 3 trial (NCT06709014) of buntanetap for e
Jul 10, 2026
BEARISH424B56/10
Annovis Bio is raising approximately $13.8M in net proceeds through a dilutive offering of 7.9M shar
May 20, 2026
BEARISH424B57/10
Annovis Bio filed a preliminary 424B5 for an underwritten offering of common stock and warrants, wit
May 19, 2026
MIXED8-K5/10
Annovis Bio reported Q1 2026 results showing increased net loss per share ($0.63 vs $0.32) and cash
May 15, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Sep 28, 2026
short_volume
Short Volume: ANVS — 58.9% short (0.4M / 0.7M)
Short: 423,758 | Exempt: 2,589 | TRF Vol: 719,422 | Short Ratio: 58.9% | Off-exchange volume (dark pool + OTC)
Sep 23, 2026
short_volume
Short Volume: ANVS — 78.5% short (0.5M / 0.6M)
Short: 468,997 | Exempt: 250 | TRF Vol: 597,506 | Short Ratio: 78.5% | Off-exchange volume (dark pool + OTC)
Sep 22, 2026
short_volume
Short Volume: ANVS — 77.8% short (0.5M / 0.6M)
Short: 456,047 | Exempt: 0 | TRF Vol: 586,100 | Short Ratio: 77.8% | Off-exchange volume (dark pool + OTC)
Sep 17, 2026
short_volume
Short Volume: ANVS — 72.4% short (0.7M / 0.9M)
Short: 676,171 | Exempt: 0 | TRF Vol: 934,506 | Short Ratio: 72.4% | Off-exchange volume (dark pool + OTC)
Sep 15, 2026
short_interest_report
Short Interest: ANVS up 21% to 6.0M shares
Settlement 2026-09-15 | Days to cover: 3.19 | ≈14.11% of shares outstanding (est.)
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $-0.33 | $-0.36–$-0.30 | 10.8% | +10.8% | 1↑ 0↓ | $0.0B | 2 |
| Next Q | $-0.23 | $-0.30–$-0.17 | 39.7% | +14.5% | 1↑ 0↓ | $0.0B | 2 |
| Current FY | $-1.45 | $-1.58–$-1.32 | -3.6% | +14.2% | 1↑ 0↓ | $0.0B | 2 |
| Next FY | $-0.86 | $-1.18–$-0.54 | 40.7% | +2.8% | 0↑ 1↓ | $0.0B | 2 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $-0.330 | — |
| 7d ago | $-0.330 | — |
| 30d ago | $-0.370 | +0.040 |
| 60d ago | $-0.440 | +0.110 |
| 90d ago | $-0.440 | +0.110 |
Institutional ownership
Which big funds own ANVS (from quarterly 13F filings) and who is adding or trimming.
39 institutional holders with $17.0M total value (9,135,529 shares) as of 2026-Q2. Top holders: MARSHALL, VANGUARD, TUDOR. Net buying activity: 8 institutions added/increased vs 5 reduced.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| MARSHALL WACE, LLP | 1,842,339 | $3.4M | 20.2% | ADD +55.1% |
| VANGUARD CAPITAL MANAGEMENT LLC | 1,647,322 | $3.1M | 18.0% | ADD +88.8% |
| TUDOR INVESTMENT CORP ET AL | 1,357,134 | $2.5M | 14.9% | — |
| RENAISSANCE TECHNOLOGIES LLC | 1,002,200 | $1.9M | 11.0% | DOUBLED +188.3% |
| TWO SIGMA INVESTMENTS, LP | 579,571 | $1.1M | 6.3% | DOUBLED +1421.7% |
| Caption Management, LLC | 474,900 | $883.3K | 5.2% | — |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 285,900 | $531.8K | 3.1% | TRIM -32.8% |
| GEODE CAPITAL MANAGEMENT, LLC | 283,817 | $528.1K | 3.1% | ADD +53.3% |
| BlackRock, Inc. | 249,856 | $464.7K | 2.7% | ADD +79.1% |
| CITADEL ADVISORS LLC | 243,682 | $453.2K | 2.7% | DOUBLED +494.5% |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| MARSHALL WACE, LLP | ADD | 1,187,499 | 1,842,339 | +55.1% | $3.4M |
| VANGUARD CAPITAL MANAGEMENT LLC | ADD | 872,381 | 1,647,322 | +88.8% | $3.1M |
| RENAISSANCE TECHNOLOGIES LLC | DOUBLED | 347,600 | 1,002,200 | +188.3% | $1.9M |
| BlackRock, Inc. | ADD | 139,533 | 249,856 | +79.1% | $464.7K |
| VANGUARD FIDUCIARY TRUST CO | ADD | 132,042 | 177,530 | +34.4% | $330.2K |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | TRIM | 218,336 | 146,804 | -32.8% | $273.1K |
| NORTHERN TRUST CORP | TRIM | 141,730 | 68,070 | -52.0% | $126.6K |
| WELLS FARGO & COMPANY/MN | DOUBLED | 14,307 | 30,307 | +111.8% | $56.4K |
| UBS Group AG | TRIM | 21,538 | 11,775 | -45.3% | $21.9K |
| Arax Advisory Partners | ADD | 4,000 | 6,500 | +62.5% | $12.1K |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
1 insiders, 4 transactions. Net $1.6M — $1.6M bought, $0.00 sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| May 20, 2026 | Hoffman Michael B | Director | BUY | 54,933 | $1.90 | $104.4K |
| May 20, 2026 | Hoffman Michael B | Director | BUY | 18,849 | $1.80 | $33.9K |
| May 20, 2026 | Hoffman Michael B | Director | BUY | 2,562 | $1.75 | $4.5K |
| Apr 2, 2026 | Hoffman Michael B | Director | BUY | 713,800 | $2.10 | $1.5M |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for ANVS.
Shares short
6,022,040
Settlement Sep 15, 2026
Change vs prior
+20.7%
Semi-monthly cycle
Days to cover
3.2
At avg daily volume
Of shares outstanding
≈14.1%
Estimate — not % of float
All ANVS filing & press-release reports (8)
- 8-K reportJul 10, 2026
- 424B5 reportMay 20, 2026
- 424B5 reportMay 19, 2026
- 8-K reportMay 15, 2026
- PRESS-RELEASE reportMay 15, 2026
- PRESS-RELEASE reportApr 10, 2026
- PRESS-RELEASE reportMar 19, 2026
- PRESS-RELEASE reportMar 16, 2026